false000177078700017707872024-01-082024-01-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 8, 2024

Logo-10x.jpg
10x Genomics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-39035
45-5614458
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
6230 Stoneridge Mall Road
Pleasanton, California 94588
(925) 401-7300
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
___________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol
Name of each exchange
on which registered
Class A common stock, par value $0.00001 per share
TXG
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


Item 2.02 Results of Operations and Financial Condition.
On January 8, 2024, 10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s preliminary fourth quarter and full year revenue for the period ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1.
The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.
Description of Exhibits
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document).


Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
10x Genomics, Inc.
By:
/s/ Eric S. Whitaker
Name:
Eric S. Whitaker
Title:
Chief Legal Officer
Date: January 8, 2024


Exhibit 99.1
a10x_logoxhorizontalxfullc.jpg
10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results
PLEASANTON, Calif., January 8, 2024 — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2023.

Preliminary, Unaudited Select Fourth Quarter 2023 Financial Results
•Revenue of approximately $184.0 million for the three months ended December 31, 2023, representing 18% growth over the corresponding prior year period.
•Instruments revenue of approximately $38.4 million, representing 72% growth over the corresponding prior year period. Instruments revenue consists of approximately $11.1 million Chromium instruments revenue and $27.2 million Spatial instruments revenue.
•Consumables revenue of approximately $140.3 million, representing 7% growth over the corresponding prior year period. Consumables revenue consists of approximately $118.1 million Chromium consumables revenue and $22.2 million Spatial consumables revenue.
•Services revenue of approximately $5.3 million, representing 129% growth over the corresponding prior year period.
Preliminary, Unaudited Select Full Year 2023 Financial Results
•Revenue of approximately $618.7 million for the year ended December 31, 2023, representing 20% growth over the prior year.
•Instruments revenue of approximately $123.5 million, representing 71% growth over the prior year. Instruments revenue consists of approximately $47.9 million Chromium instruments revenue and $75.6 million Spatial instruments revenue.
•Consumables revenue of approximately $479.6 million, representing 10% growth over the prior year. Consumables revenue consists of approximately $420.3 million Chromium consumables revenue and $59.2 million Spatial consumables revenue.
•Services revenue of approximately $15.7 million, representing 86% growth over the prior year.
•Increased cumulative instruments sold to more than 5,900 as of the end of 2023, which includes over 5,150 Chromium instruments, over 500 Visium instruments and over 250 Xenium instruments.
Preliminary Revenue Subject to Adjustment
10x Genomics, Inc. has not completed preparation of its financial statements for the fourth quarter or full year of 2023. The revenue estimates presented in this news release for the quarter and year ended December 31, 2023 are preliminary and unaudited and are thus inherently uncertain and subject to change as we complete preparation of our financial statements for the fourth quarter and year ended December 31, 2023. 10x Genomics, Inc. is in the process of completing its customary year-end close and review procedures as of and for the quarter and year ended December 31, 2023, and there can be no assurance that final results for these periods will not differ from these estimates. During the course of the preparation of 10x Genomics, Inc.'s consolidated financial statements and related notes as of and for the year ended December 31, 2023, we or our independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary financial estimates presented herein.
10x Genomics, Inc. plans to report final financial results for the quarter and year ended December 31, 2023 in its February 2024 earnings call.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
1
a10x_logoxhorizontalxfullc.jpg
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “see,” “estimate,” “predict,” “potential,” “would,” “likely,” “seek” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.’s expected financial results. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.’s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s most recently-filed 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
2
v3.23.4
Cover
Jan. 08, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 08, 2024
Entity Registrant Name 10x Genomics, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39035
Entity Tax Identification Number 45-5614458
Entity Address, Address Line One 6230 Stoneridge Mall Road
Entity Address, City or Town Pleasanton
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94588
City Area Code 925
Local Phone Number 401-7300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, par value $0.00001 per share
Trading Symbol TXG
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001770787
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more 10x Genomics Charts.
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more 10x Genomics Charts.